Global Leader in Oral Delivery of Therapeutic Proteins

We are a clinical stage company developing oral peptide and protein replacement therapies for significant unmet needs where an oral tablet holds the potential to transform the standard of care.

LATEST NEWS

Press Releases

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Phase 2 Published in JBMR

Entera Bio Featured in BioTeusdays

Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

Events

Entera Bio to Participate in Upcoming Investor and Scientific Conferences – HCW, ASBMR, and Evercore

Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact

Therapeutic Areas

Osteoporosis

Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, which leads to greater fragility and an increase in fracture risk.

Hypoparathyroidism is a rare condition in which the parathyroid glands fail to produce sufficient amounts of parathyroid hormone or the parathyroid hormone produced lacks biologic activity.

SBS & Obesity Programs

We have a collaboration agreement with OPKO to leverage our N-Tab™ technology for the development of an oral GLP-2 for Short Bowel Syndrome and GLP-1/glucagon for obesity.

ABOUT US

Entera is Daring Courageous Fierce

Entera leverages a disruptive and proprietary oral delivery technology platform (N-Tab™) that is designed to stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream.

Our pipeline includes five differentiated, first-in-class oral peptide programs expected to enter the clinic by 2025.